Mutations in KRAS, a small GTPase that regulates MAPK/ERK signaling, define the largest genetically-defined subset of non-small cell lung cancer (NSCLC), representing 25–30% of all lung adenocarcinomas1. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.